|Bid||6.85 x 800|
|Ask||7.35 x 4000|
|Day's Range||6.99 - 7.25|
|52 Week Range||4.86 - 13.21|
|Beta (3Y Monthly)||2.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 13, 2017 - Nov 17, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.67|
CLEVELAND, April 18, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today that the company has partnered with Minogue Medical Inc., a leading Canadian distributor of surgical devices, operating room disposables, hospital equipment, and simulators for medical education. As part of the exclusive distribution agreement, Minogue Medical will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system throughout Canada.
CLEVELAND, April 17, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) and Device Technologies Australia Pty Ltd (Device Technologies) announced today a partnership in which Device Technologies, the largest independent distributor in Australasia, will market, sell, and support ViewRay's MRIdian MRI-guided radiation therapy system. "Device Technologies is the ideal partner to bring the benefits of the MRIdian System to one of the biggest and best healthcare markets in the world," said Jim Alecxih, Chief Commercial Officer at ViewRay. MRIdian provides continuous high-contrast imaging of soft tissue during radiation therapy treatment to help clinicians position the patient, track tumor and anatomical motion, and accurately target treatment.
ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8616638.
CLEVELAND, April 11, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the publication of a retrospective analysis of outcomes for the stereotactic treatment of locally advanced pancreatic cancer using precise, high-dose MRI-guided radiation therapy delivered with MRIdian's on-table adaptive dose planning system. The study, published in Cancer Medicine, and led by Soumon Rudra, M.D. from Washington University in St. Louis, demonstrated enhanced overall survival while resulting in lower levels of toxicity compared to lower-dose, mostly non-adaptive treatment.
ViewRay, Inc.'s (NASDAQ:VRAY) most recent earnings announcement in December 2018 indicated company earnings became less negative compared to the previous year's level - great news for investors Investors may findRead More...
The Oakwood Village, Ohio-based company said it had a loss of 17 cents per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research ...
CLEVELAND , March 14, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the fourth quarter and full year ended December 31, 2018 . Full Year 2018 Highlights: Total ...
NEW YORK, NY / ACCESSWIRE / March 14, 2019 / ViewRay, Inc. (NASDAQ: VRAY ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 14, 2019, 2018 at 4:30 PM ...
Proprietary Technology from ViewRay Enables Imaging and Treatment Enhancements CLEVELAND , Feb. 21, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), announced today that the company received 510(k) clearance ...
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
CLEVELAND , Feb. 14, 2019 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its fourth quarter and full year 2018 financial results. ViewRay will hold a conference ...
As one of the world's leading cancer centers, Siteman is known for pioneering the advancement and adoption of innovative technologies with a focus on improving patient care and outcomes. "We congratulate the Siteman team on reaching this milestone and commend them for their thought-leadership, innovation and commitment to cutting-edge cancer care," said Scott Drake, President and Chief Executive Officer of ViewRay.
CLEVELAND, Jan. 7, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2018. The preliminary results have not been audited and are subject to change. This resulted in total fourth quarter 2018 revenue of approximately $21 million, compared to fourth quarter 2017 revenue of $19.9 million, primarily from four revenue units.
CLEVELAND, Jan. 4, 2019 /PRNewswire/ -- ViewRay, Inc. (VRAY) announced today the enrollment of the first patient in the Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) Trial, a multi-center, prospective clinical trial for locally advanced or borderline pancreatic cancer. The trial will explore the clinical benefits of precise, high dose radiation therapy enabled by MR-guidance combined with daily on-table adaptation in the treatment of pancreatic cancer. Retrospective analysis of precise, high-dose MR-guided radiation therapy delivered using adaptive dose planning has shown promising results with locally advanced pancreatic cancer, suggesting the potential for improving overall survival relative to patients receiving lower radiation doses, without increasing the rate of serious gastrointestinal toxicity. The compelling nature of the retrospective data prompted the SMART trial, aimed at investigating in a controlled, prospective manner, the robustness of this outcome and tracking quality of life over a 5-year trial period.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also plenty of examples of share prices declining precipitously after insiders Read More...
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
CLEVELAND , Dec. 10, 2018 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced that the Company will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California . ...
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.